Actively Recruiting
Helicobacter Pylori Eradication and Follow-up
Led by Shanghai Zhongshan Hospital · Updated on 2021-09-30
4447
Participants Needed
1
Research Sites
247 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This randomized controlled clinical trial will estimate the eradication efficacy of different therapy for Helicobacter pylori treatment. The completion of this trial will expand new therapy for the treatment of Helicobacter pylori, which can not only ensure clinical efficacy, but also reduce the use of antibiotics.
CONDITIONS
Official Title
Helicobacter Pylori Eradication and Follow-up
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily agree to participate and sign informed consent
- Aged 18 to 75 years old on the day of consent
- Confirmed Helicobacter pylori infection by 13C-urea breath test or rapid urease test
You will not qualify if you...
- Severe heart, lung, kidney, liver, blood, nerve, endocrine, or psychiatric diseases
- Refusal to participate by patient or guardian
- Alcohol or drug abuse or poor compliance as judged by doctor
- Use of antibiotics, bismuth, proton pump inhibitors, or traditional Chinese medicine within 4 weeks before treatment
- Pregnant or breastfeeding women
- Active peptic ulcer
- Allergy to any study drugs
- Any other condition unsuitable for recruitment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
Q
Qi Chen, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
10
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here